Io­n­is launch­es an ear­ly-stage tau drug study for Alzheimer’s, pick­ing up $10M from Bio­gen

Af­ter amy­loid be­ta, the sec­ond big tar­get in Alzheimer’s dis­ease cen­ters on tox­ic ac­cu­mu­la­tions of tau, pos­si­bly work­ing hand-in-hand with a-be­ta to fry peo­ple’s mem­o­ries. And to­day Io­n­is $IONS says that it’s pick­ing up a $10 mil­lion mile­stone from its part­ners at Bio­gen to be­gin an ear­ly-stage study that will set out to try and de­ter­mine if its an­ti­sense tech can make a dif­fer­ence in dis­ease pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER